Saturday, February 18, 2017

Roche says Phase II trial supports twin treatment for kidney cancer

VIENNA, Feb 18 (Reuters) - Swiss pharmaceuticals company

Roche said on Saturday that a combination of its

immunotherapy drug Tecentriq and its blockbuster cancer drug

Avastin had shown encouraging results in a Phase II trial in

treating a type of kidney cancer.

Read more

No comments:

Post a Comment